Aprea Therapeutics (NASDAQ:APRE) Issues Earnings Results, Beats Estimates By $0.20 EPS

Aprea Therapeutics (NASDAQ:APRE) posted its earnings results on Tuesday. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.20, Zacks reports. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.15 million.

Aprea Therapeutics Trading Down 3.1 %

Shares of NASDAQ APRE opened at $2.19 on Wednesday. The company has a market capitalization of $11.90 million, a price-to-earnings ratio of -0.78 and a beta of 0.82. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $6.80. The firm has a 50-day moving average of $3.12 and a two-hundred day moving average of $3.26.

Analyst Ratings Changes

Several equities analysts have commented on APRE shares. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research note on Wednesday, January 15th. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research report on Tuesday.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.